Key result
Sutureless aortic valve replacement is linked to ~39% lower total costs compared to TAVI.
Why the study?
SU-AVR and TAVI show similar all-cause mortality with different adverse effect patterns in elderly patients with aortic stenosis, but comparisons of their costs are needed.
Does transcatheter aortic valve implantation compared to sutureless aortic valve replacement reduce costs in elderly patients with aortic stenosis?
Cohort (n=268)
No
Does transcatheter aortic valve implantation compared to sutureless aortic valve replacement reduce costs in elderly patients with aortic stenosis?
Answers are grounded in this paper and cite their sources.
While TAVI reduces length of stay and non-device hospital costs, SU-AVR remains overall cost-saving due to significantly lower device costs.
AIMS: Sutureless aortic valve replacement (SU-AVR) and transcatheter aortic valve implantation (TAVI) are both viable therapeutic interventions for aortic stenosis in elderly patients. Meta-analyses show similar all-cause mortality for both techniques albeit with a different pattern of adverse effects. This study means to compare costs and, to a lesser extent, clinical outcomes of both techniques. METHODS: A retrospective single-centre analysis was performed for patients receiving SU-AVR or TAVI from 2008 to 2019. Perioperative clinical data were collected from patient files. Costs were assessed by a cost allocation tool. In an attempt to avoid confounding, propensity score matching was carried out. After matching, there were 61 patients per treatment group. Length of stay was significantly longer in the SU-AVR group. Excluding device costs, total expenses for SU-AVR (median: €11,630) were significantly higher than TAVI (median: €9240). For both groups, these costs were mostly incurred on intensive care units, followed by nursing units. Non-medical staff was the largest contributor to expenses. Including device costs, SU-AVR (median: €14,683) was shown to be cost-saving compared to TAVI (median: €24,057). CONCLUSIONS: To conclude, we found SU-AVR to be cost-saving compared to TAVI, largely due to higher device costs associated with the latter. Excluding device costs, TAVI was associated with lower expenses and shorter length of stay. Non-medical staff was the largest source of costs, suggesting length of stay to be a major financial determinant.
No takes yet. Share an insight, caveat, or question.
Paepe et al. (2023) conducted a cohort in Aortic stenosis (n=268). Sutureless aortic valve replacement (SU-AVR) vs. Transcatheter aortic valve implantation (TAVI) was evaluated on Total expenses including device costs. Sutureless aortic valve replacement was cost-saving compared to transcatheter aortic valve implantation when including device costs (median €14,683 vs €24,057).
Synapse has enriched 10 related papers. Consider them for comparative context: